Login to Your Account



Regeneron Plummets On Early Phase III Results With Axokine

By Randall Osborne


Tuesday, April 1, 2003

Preliminary results from Regeneron Pharmaceutical Inc.'s Phase III trial with the obesity drug Axokine are being called mixed, but the market's reaction was unambiguous, taking away 56.6 percent of the stock's value.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription